Display options
Cite
Li D, Wu QJ, Bi FF, et al. Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. Am J Transl Res. 2016;8(3):1601-8
Li, D., Wu, Q. J., Bi, F. F., Chen, S. L., Zhou, Y. M., Zhao, Y., & Yang, Q. (2016). Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. American journal of translational research, 8(3), 1601-8.
Li, Da, et al. "Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer." American journal of translational research vol. 8,3 (2016): 1601-8.
Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, Yang Q. Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016. PMID: 27186285; PMCID: PMC4859644.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016.

Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.

American journal of translational research

Da Li, Qi-Jun Wu, Fang-Fang Bi, Si-Lei Chen, Yi-Ming Zhou, Yue Zhao, Qing Yang

Affiliations

  1. Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University Shenyang 110004, China.
  2. Department of Clinical Epidemiology, Shengjing Hospital of China Medical University Shenyang 110004, China.
  3. Department of Medicine, Brigham and Women's Hospital, Harvard Institutes of Medicine, Harvard Medical School Boston, MA 02115, USA.
  4. Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University Shenyang 110001, China.

PMID: 27186285 PMCID: PMC4859644

Abstract

There is accumulating evidence that breast cancer 1 (BRCA1), sirtuin 1 (SIRT1), and epidermal growth factor receptor (EGFR) help to modulate cisplatin cytotoxicity. The role of dynamic crosstalk among BRCA1, SIRT1, and EGFR in cisplatin sensitivity remains largely unknown. We found that BRCA1, SIRT1, and EGFR levels were increased in cisplatin-resistant ovarian cancers compared with those in cisplatin-sensitive ovarian cancers. Hypomethylation in the BRCA1 promoter was associated with BRCA1 activation, significantly elevated SIRT1 levels, decreased nicotinamide adenine dinucleotide (NAD)-mediated SIRT1 activity, and decreased EGFR levels. Treatment with 5 and 10 μg/ml cisplatin induced a gradual increase in BRCA1 and SIRT1 levels and a gradual decrease in NAD levels and NAD-mediated SIRT1 activity, whereas EGFR levels were increased or decreased by treatment with 5 or 10 μg/ml cisplatin, respectively. The overexpression of SIRT1 or the enhancement of SIRT1 activity synergistically enhanced the BRCA1-mediated effects on EGFR transcription. In contrast, the knockdown of SIRT1 or the inhibition of SIRT1 activity inhibited the BRCA1-mediated effects on EGFR transcription. BRCA1 regulates EGFR through a BRCA1-mediated balance between SIRT1 expression and activity. Those results improve our understanding of the basic molecular mechanism underlying BRCA1-related cisplatin resistance in ovarian cancer.

Keywords: BRCA1; EGFR; SIRT1; cisplatin; ovarian cancer

References

  1. Breast Cancer Res. 2014 Sep 17;16(5):435 - PubMed
  2. Sci Rep. 2014 Oct 17;4:6666 - PubMed
  3. Oncotarget. 2015 Jun 10;6(16):14456-71 - PubMed
  4. Oncotarget. 2014 Aug 30;5(16):6620-32 - PubMed
  5. Oncogene. 2015 Aug 13;34(33):4333-46 - PubMed
  6. Cell Cycle. 2014;13(21):3442-9 - PubMed
  7. J Exp Clin Cancer Res. 2013 Dec 09;32:102 - PubMed
  8. Oncotarget. 2014 Mar 15;5(5):1315-25 - PubMed
  9. J Thorac Dis. 2015 Apr;7(4):711-9 - PubMed
  10. Cell Cycle. 2014;13(16):2564-71 - PubMed
  11. Sci Rep. 2015 Nov 16;5:15911 - PubMed
  12. Am J Cancer Res. 2015 Feb 15;5(3):1199-206 - PubMed
  13. J Biol Chem. 2014 Mar 28;289(13):9247-53 - PubMed
  14. Mol Cancer. 2014 Feb 06;13:26 - PubMed
  15. Lab Invest. 2015 Dec;95(12):1363-73 - PubMed
  16. Oncogene. 2015 Jun 4;34(23 ):3036-52 - PubMed
  17. J Pharmacol Exp Ther. 2015 Aug;354(2):142-51 - PubMed
  18. J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8 - PubMed
  19. Int J Cancer. 2016 Feb 15;138(4):891-900 - PubMed
  20. J Pharmacol Exp Ther. 2014 Aug;350(2):243-56 - PubMed
  21. Mayo Clin Proc. 2010 Dec;85(12):1111-20 - PubMed
  22. PLoS One. 2013 Jun 21;8(6):e67313 - PubMed
  23. Oncotarget. 2015 Jun 20;6(17):14885-904 - PubMed
  24. Cancer Res. 2014 Jan 1;74(1):298-308 - PubMed

Publication Types